Castillo-Ledesma N, Viana-Cora A, López-Simón E, Corriols-Noval P, Morales-Angulo C

Language: Spanish
References: 0
Page: 49-51
PDF size: 111.74 Kb.

ABSTRACT

Background: About 15% of patients with Meniere’s disease have poor control of their symptoms with medical treatment and require invasive treatments. Intratympanic gentamicin injection is one of the most widely used in Meniere’s disease unresponsive to medical treatment.
Objective: To determine whether it is useful to conduct a study to find the mutation A1555G in the MTRNR1 mitochondrial DNA gene in Ménière’s disease patients who will be treated with intratympanic gentamicin.
Material and Method: A prospective, cross-sectional, observational study, done from 2013 to 2015, including patients with definite Meniere’s disease, followed from 6 months to 12 years. A genetic study was performed to all them to find if they had the A1555G mutation of the MTRNR1 gene.
Results: There were included 40 patients. No patient had the A1555G mutation in the MTRNR1 gene. Seven patients had a family history of hearing loss (2 maternally).
Conclusions: It is not indicated to make a routine genetic study to patients with Meniere’s disease in the absence of a family history of ototoxic drug or maternal hearing loss.